Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?

Authors

  • Coralia N. Mihu MD,

    Corresponding author
    1. Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • The University of Texas M. D. Anderson Cancer Center, Department of Infectious Diseases, Infection Control and Employee Health, 1515 Holcombe Boulevard, Houston, TX 77030
    Search for more papers by this author
  • Christelle Kassis MD,

    1. Division of Infectious Diseases, The University of Texas Health Science Center at Houston, Houston, Texas
    Search for more papers by this author
  • Elizabeth R. Ramos MD,

    1. Division of Infectious Diseases, The University of Texas Health Science Center at Houston, Houston, Texas
    Search for more papers by this author
  • Ying Jiang MD,

    1. Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    Search for more papers by this author
  • Ray Y. Hachem MD,

    1. Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    Search for more papers by this author
  • Issam I. Raad MD

    1. Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    Search for more papers by this author

Abstract

BACKGROUND:

In vitro and in vivo studies suggested that combination of lipid formulation of amphotericin B (L-AMB) and echinocandins may have a synergistic or additive effect against Aspergillus. Furthermore, clinical studies suggested that this combination may improve response of invasive aspergillosis (IA).

METHODS:

Between August 1993 and June 2008, the authors identified a total of 159 patients with hematological malignancies who received salvage therapy for IA, with L-AMB alone, echinocandins alone, or a combination of L-AMB and echinocandins. Clinical characteristics, response to salvage therapy, and death up to 12 weeks after initiation of salvage therapy were retrospectively determined for all patients.

RESULTS:

Seventy patients received salvage therapy with L-AMB, 18 patients received echinocandins alone (89% of whom received caspofungin), and 71 patients received the combination therapy of amphotericin B and echinocandins (90% of who received caspofungin). The 3 salvage treatment groups were comparable in regard to clinical characteristics; graft versus host disease was more frequently encountered in the echinocandin group, whereas more patients in the L-AMB and combination groups had neutropenia and received immunotherapy. The response to salvage therapy was better in the echinocandin group (9% L-AMB, 28% echinocandins, and 21% for combination therapy). The 3 groups had a comparable rate of Aspergillus-related death (58%-64%) and overall mortality (61%-67%).

CONCLUSIONS:

The combination of L-AMB and echinocandins offered no advantage in terms of improving response or reducing mortality over either drug alone. Hence, this combination will only add to the cost of therapy without any improvement in outcome in patients with hematological malignancies. Cancer 2010. © 2010 American Cancer Society.

Ancillary